Royalty Pharma plc (RPRX)

27,61 +0,15 (+0,55%) Börsenschluss: 04:00PM EDT

Royalty Pharma plc

110 East 59th Street
New York, NY 10022
United States
212 883 0200
https://www.royaltypharma.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Pablo Gerardo Legorreta	Founder, Chairman of the Board & CEO	N/A	N/A	1965
Mr. Terrance P. Coyne	Executive VP & CFO	4,35M	N/A	N/A
Mr. George Wingate Lloyd	Executive VP of Investments & Chief Legal Officer	4,35M	N/A	1960
Mr. Christopher Hite	Vice Chairman & Executive VP	4,35M	N/A	1967
Dr. Marshall Jonathan Urist M.D., Ph.D.	Executive VP and Head of Research & Investments	4,35M	N/A	N/A
Mr. Arthur Richard McGivern J.D.	Executive Vice President of Investments & General Counsel	N/A	N/A	N/A
Mr. Ashwin Pai M.D.	Executive Vice President of Investments	N/A	N/A	N/A
Ms. Kristin Stafford	Senior VP & Chief Accounting Officer	N/A	N/A	1983
Mr. Eric Cornelius Schneider	Senior VP & Chief Technology Officer	N/A	N/A	N/A
Dr. James Folmar Reddoch Ph.D.	Executive VP of Investments & Chief Scientific Officer	3,4M	N/A	1970

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Corporate Governance

Royalty Pharma plcs ISS Governance QualityScore, Stand 1. April 2024, lautet 5. Die grundlegenden Scores sind Audit: 5, Vorstand: 5, Shareholderrechte: 6, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.